Analyst Price Targets — ESPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2026 7:20 pm | — | Jefferies | $3.28 | $3.11 | TheFly | Esperion downgraded to Hold from Buy at Jefferies |
| May 1, 2026 6:01 pm | — | Piper Sandler | $3.16 | $3.11 | TheFly | Esperion downgraded to Neutral from Overweight at Piper Sandler |
| May 1, 2026 1:38 pm | — | H.C. Wainwright | $3.16 | $3.11 | TheFly | Esperion downgraded to Neutral from Buy at H.C. Wainwright |
| May 1, 2026 12:44 pm | — | Cantor Fitzgerald | $3.16 | $2.00 | TheFly | Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald |
| November 24, 2025 10:30 pm | — | Piper Sandler | $9.00 | $3.17 | TheFly | Esperion initiated with an Overweight at Piper Sandler |
| September 25, 2025 6:15 pm | Kristen Kluska | Cantor Fitzgerald | $9.00 | $2.56 | TheFly | Esperion price target raised to $9 from $7 at Cantor Fitzgerald |
| December 17, 2024 11:36 am | Kristen Kluska | Cantor Fitzgerald | $8.00 | $3.04 | TheFly | Esperion initiated with an Overweight at Cantor Fitzgerald |
| May 4, 2022 12:00 am | Serge Belanger | Needham | $12.00 | $6.53 | TipRanks Contributor | Esperion Therapeutics Rises on Upbeat Q1 Results |
| May 4, 2021 12:00 am | Derek Archila | Wells Fargo | $20.00 | $25.59 | Benzinga | Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for ESPR

Stockholders of Esperion Therapeutics NASDAQ: ESPR approved the company's merger agreement with Essence Parent and Essence MergerCo at a special meeting held virtually on July 8, 2026, according to remarks delivered during the meeting.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ESPR.
U.S. House Trading
No House trades found for ESPR.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
